In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The role of st2 in patients with st segment elevation myocardial infarction

Session Poster Session 1

Speaker Associate Professor Irina Vishnevskaya

Event : Heart Failure 2017

  • Topic : basic science
  • Sub-topic : Basic Science
  • Session type : Poster Session

Authors : IR Vishnevskaya (Kharkiv,UA), OV Petyunina (Kharkiv,UA), MP Kopytsya (Kharkiv,UA), YV Hilova (Kharkiv,UA), LL Peteneva (Kharkiv,UA)

Authors:
IR Vishnevskaya1 , OV Petyunina1 , MP Kopytsya1 , YV Hilova1 , LL Peteneva1 , 1Government institution“L.T. Malaya Therapy National institute of the National academy of medical sci - Kharkiv - Ukraine ,

Citation:
European Journal of Heart Failure ( 2017 ) 19 ( Suppl. S1 ), 129

The biomarker ST2 is a member of interleukin family, which is expressed by cardiomyocytes in two forms – membrane—bound (ST2L) and soluble isoform (sST2). sST2 is a «decoy-receptor» for interleukin 33, its level tells us about the left ventricular (LV) remodeling grade and the heart failure’s stage.

Purpose: to investigate the role of sST2 in patients with ST segment elevation myocardial infarction (STEMI).

Methods: 65 patients with STEMI were enrolled to the study. Among them are 83,1% male and 16,9% female. Mean age was 57 ± 2,3 years. All patients underwent a baseline investigation which includes: standard electrocardiography, echocardiography, angiography with stenting of the infarct-related artery. In addition, the level of sST2 was determined during the first day of the disease via ELISA test.

Results: Correlation analysis of the studied parameters showed significant negative correlation between the level of sST2 and the ejection fraction of LV (r=-0,5; p =0,0001), also the rank of correlation coefficient was identified between sST2 and the end diastolic diameter of LV (r=0,31; p=0,03), and the end systolic diameter of LV (r=0,4; p=0,007) which is consistent with the role of sST2 in the progression of ventricular remodeling. The level of sST2 was significantly higher in females compared to males, 98,41±36,64 ng/ml and 73,54±29,35 ng/ml, respectively. After comparing the levels of sST2 accordingly to presence or absence of a stable angina before index hospitalization, the patients with a history of stable angina had a significantly lower level of sST2 (p=0,01). Patients with anterior STEMI had higher concentration of sST2 (88,84±33,66 ng/ml) than those with inferior STEMI - 69,38±23,81 ng/ml, p=0,003. For patients with two-vessel coronary artery disease (CAD) sST2 level was 118,26±57,67 ng/ml, for those with three-vessel CAD - 61,79±31,98 ng/ml (p=0,002).

Conclusions: Females are more vulnerable for an early postinfarction remodeling. Higher level of sST2 in patients with anterior STEMI is related to increased infarct zone. Low level of sST2 verifies the patients with a good developing coronary collateral circulation with a history of stable angina. The number of injured coronary artery influences on the heart remodeling – two-vessel injury associated with more expressed remodeling compared with multi-vessel in patients with STEMI.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are